Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: A retrospective study from GIMEMA Multiple Myeloma Working Party

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1499-1502

  D'Arena, G ^a   Valentini, C G ^b   Pietrantuono, G ^a   Guariglia, R ^a   Martorelli, M C ^a   Mansueto, G ^a   Villani, O ^a   Onofrillo, D ^c   Falcone, A ^d   Specchia, G ^e   Semenzato, G ^f   Di Renzo, N ^g   Mastrullo, L ^h   Venditti, A ⁱ   Ferrara, F ^j   Palumbo, A ^k   Pagano, L ^b   Musto, P ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Hospital of Pescara   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g VITO FAZZI HOSPITAL   (Italy)

^h San Gennaro Hospital   (Italy)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

^j CARDARELLI HOSPITAL   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Bortezomib; Chemotherapy; Multiple myeloma; Primary plasma cell leukemia

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIMARY PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

EID: 84861735445     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr480     Document Type: Article

References (38)

1. Sher T, Miller KC, Deeb G et al. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol 2010; 150: 418-427.
2. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev 2011; 25: 107-112.
3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
4. McKenna RW, Kyle RA, Kuehl WM et al. Plasma cell neoplasms. In Swerdlow SH, Campo E, Harris NL et al. (eds), WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC 2008; 200-213.
5. Noel P, Kyle RA. Plasma cell leukaemia: an evaluation of response to therapy. Am J Med 1987; 83: 1062-1067.
6. Bernasconi C, Castelli G, Pagnucco G, Brusamolino E. Plasma cell leukemia: a report on 15 patients. Eur J Haematol Suppl 1989; 51: 76-83.
7. Musto P, Greco MM, Falcone A, Carotenuto M. Treatment of plasma cell leukaemia and resistant/relapsed multiple myeloma with vincristine, mitoxantrone and dexamethasone (VMD protocol). Br J Haematol 1991; 79: 655-656.
8. Dimopoulos MA, Palumbo A, Delasalle KB et al. Primary plasma cell leukemia. Br J Haematol 1994; 88: 754-760.
9. Garcia-Sanz R, Orfao A, Gonzales M et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy and cytogenetic characteristics. Blood 1999; 93: 1032-1037.
10. Costello R, Sainty D, Bouabdallah R et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res 2001; 25: 103-107.
11. Christou L, Hatzimichael E, Chaidos A et al. Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. Eur J Haematol 2001; 67: 51-53.
12. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 2002; 81: 363-367.
13. Jimenez-Zepeda VH, Dominguez VJ. Plasma cell leukemia: a rare condition. Ann Hematol 2006; 85: 263-267.
14. Saccaro S, Fonseca R, Veillon DM et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78: 288-294.
15. Mahindra A, Vesole D, Kalycio ME et al. Autologous hematopoietic stem cell transplantation (HCT) is a safe and effective treatment for primary plasma cell leukemia: the CIBMTR experience. Blood 2009; 114: (Abstr 532).
16. Drake MB, Iacobelli S, van Biezen A et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010; 95: 804-809.
17. Musto P, Rossini F, Gay F et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109: 2285-2290.
18. Durie BG, Harousseau JL, San Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
19. Musto P, Pagano L, Petrucci MT et al. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 2011 June 28 (epub ahead of print).
20. Tiedemann RE, Gonzalez-Paz N, Kyle RA et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044-1052.
21. Ramsingh G, Mehan P, Luo J et al. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 2009; 115: 5734-5739.
22. Pagano L, Valentini CG, De Stefano V et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 2011; 22: 1628-1635.
23. Esparis-Ogando A, Alegre A, Aguado B et al. Bortezomib is an efficient agent in plasma cell leukemia. Int J Cancer 2005; 114: 665-667.
24. Finnegan DP, Kettle P, Drake M et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006; 47: 1670-1673.
25. Ataergin S, Arpaci F, Kaya A et al. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol 2006; 81: 986-987.
26. Grassinger J, Sudhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006; 85: 132-133.
27. Ali R, Beksac M, Ozkalemkas F et al. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymphoma 2007; 48: 1426-1428.
28. Kim SJ, Kim J, Cho Y et al. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol 2007; 37: 382-384.
29. Krüger WH, Kiefer T, Schüller F et al. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie 2007; 30: 193-195.
30. Capalbo S, Chiefa A, Delia M et al. Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement. Acta Oncol 2007; 46: 262-264.
31. Telek B, Méhes L, Batár P et al. Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation. Orv Hetil 2008; 149: 1957-1959.
32. Katodrituou E, Verrou E, Gastari V et al. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome. Leuk Res 2008; 32: 1153-1156.
33. Al-Nawaki C, Tamburini J, Bardet V et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma 2008; 49: 2012-2014.
34. Bernardeschi P, Pirrotta MT, Montenora I et al. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record. Leuk Res 2010; 34: 104-105.
35. Libby E, Candelaria-Quintana D, Moualla H et al. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol 2010; 85: 733-734.
36. Mele G, Pinna S, Melpignano A, Quarta G. Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens. Clin Ther 2010; 32: 915-919.
37. Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005; 25: 1820-1825.
38. Musto P, D'Auria F, Petrucci MT et al. Efficacy and safety of lenalidomide in combination with low dose dexamethasone (LD) as first line treatment of primary plasma cell leukemia (PPCL). Haematologica 2011; 96 (suppl 2): O303.